Molecular mechanisms underlying mood stabilization in manic-depressive illness: The phenotype challenge

American Journal of Psychiatry

Volumn 156, Issue 10, 1999, Pages 1506-1514

  Ikonomov, Ognian C ^a   Manji, Husseini K ^b  

^a WAYNE STATE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOGEN SYNTHASE; LITHIUM; PROTEIN BCL 2; PROTEIN KINASE C;

CIRCADIAN RHYTHM; ENZYME INHIBITION; GENE EXPRESSION; HUMAN; MANIC DEPRESSIVE PSYCHOSIS; MENTAL DISEASE; MOOD; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; REVIEW;

EID: 0032870743     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/ajp.156.10.1506     Document Type: Review

References (70)

1. Goodwin FK, Jamison KR: Manic-Depressive Illness. New York, Oxford University Press, 1990
2. Baldessarini RJ, Tondo L, Hennen J: Effects of lithium treatment and its discontinuation in bipolar manic-depressive disorders. J Clin Psychiatry 1999; 60(suppl 2):77-84
3. Lenox RH, Manji HK: Lithium, in American Psychiatric Press Textbook of Psychopharmacology, 2nd ed. Edited by Schatzberg AF, Nemeroff CB. Washington, DC, American Psychiatric Press, 1998, pp 379-429
4. Manji HK, Potter WZ, Lenox RH: Signal transduction pathways: molecular targets for lithium's actions. Arch Gen Psychiatry 1995; 52:531-543
5. Jope RS: Anti-bipolar therapy: mechanism of action of lithium. Mol Psychiatry 1999; 4:117-128
6. Wang JF, Young LT, Li PP, Warsh JJ: Signal transduction abnormalities in bipolar disorder, in Bipolar Disorder: Biological Models and Their Clinical Applications. Edited by Young LT, Joffe RT. New York, Marcel Dekker, 1997, pp 41-80
7. Lenox RH: Role of receptor coupling to phosphoinositide metabolism in the therapeutic action of lithium. Adv Exp Biol Med 1987; 221:515-530
8. Hyman SE, Nestler EJ: Initiation and adaptation: a paradigm for understanding psychotropic drug action. Am J Psychiatry 1996; 153:151-162
9. Lifton RP: Genetic determinants of human hypertension. Proc Natl Acad Sci USA 1995; 92:8545-8551
10. Takahashi JS, Kornhauser JM, Koumenis C, Eskin A: Molecular approaches to understanding circadian oscillators. Annu Rev Physiol 1993; 55:729-754
11. Reisine T, Zatz M: Interactions among lithium, calcium, diacylglycerides, and phorbol esters in the regulation of adrenocorticotropin hormone release from AtT-20 cells. J Neurochem 1987; 49:884-889
12. Hokin LE, Dixon JF, Los GV: A novel action of lithium: stimulation of glutamate release and inositol 1,4,5 trisphosphate accumulation via activation of the N-methyl D-aspartate receptor in monkey and mouse cerebral cortex slices. Adv Enzyme Regul 1996; 36:229-244
13. Balla T, Enyedi P, Hunyady L, Spat A: Effects of lithium and angiotensin-stimulated phosphatidylinositol turnover and aldosterone production in adrenal glomerulosa cells: a possible causal relationship. FEBS Lett 1984; 171:179-182
14. Menkes HA, Baraban JM, Freed AN, Snyder SH: Lithium dampens neurotransmitter response in smooth muscle: relevance to action in affective illness. Proc Natl Acad Sci USA 1986; 83:5727-5730
15. Klein PS, Melton DA: A molecular mechanism for the effect of lithium on development. Proc Natl Acad Sci USA 1996; 93: 8455-8459
16. Klemfuss H: Rhythms and the pharmacology of lithium. Pharmacol Ther 1992; 56:53-78
17. Richter-Levin G, Markram H, Segal M: Spontaneous recovery of deficits in spatial memory and cholinergic potentiation of NMDA in CA1 neurons during chronic lithium treatment. Hippocampus 1992; 2:279-286
18. Schmidt J: Lithium suppresses seizure susceptibility in pentylenetetrazol-kindled rats. Biomed Biochim Acta 1986; 45: 1167-1172
19. Honchar MP, Olney JW, Sherman WR: Systemic cholinergic agents induce seizures and brain damage in lithium-treated rats. Science 1983; 220:323-325
20. Nonaka S, Hough CJ, Chuang DM: Chronic lithium treatment robustly protects neurons in the central nervous system against excitotoxicity by inhibiting N-methyl-D-aspartate receptor-mediated calcium influx. Proc Natl Acad Sci USA 1998;95:2642-2647
21. Chen RW, Chuang DM: Long term lithium treatment suppresses p53 and Bax expression but increases Bcl-2 expression: a prominent role in neuroprotection against excitotoxicity. J Biol Chem 1999; 274:6039-6042
22. Manji HK, Moore GJ, Chen G: Lithium at 50: have the neuroprotective effects of this unique cation been overlooked? Biol Psychiatry (in press)
23. Dichtl B, Stevens A, Tollerey D: Lithium toxicity in yeast is due to the inhibition of RNA processing enzymes. EMBO J 1997; 16:7184-7195
24. Anai H, Ueta Y, Serino R, Bomura M, Kabashima N, Shibuya I, Takasugi M, Nakashima Y, Yamashita H: Upregulation of the expression of vasopressin gene in the paraventricular and supraoptic nuclei of the lithium-induced diabetes insipidus rat. Brain Res 1997; 772:161-166
25. Berridge MJ, Downes CP, Hanley MR: Neuronal and developmental actions of lithium: a unifying hypothesis. Cell 1989; 59: 411-419
26. Hedgepeth CM, Conrad LJ, Zhang J, Huang HC, Lee VM, Klein PS: Activation of the Wnt signaling pathway: a molecular mechanism for lithium action. Dev Biol 1997; 185:82-91
27. Fisher SK, Heacock AM, Agranoff BW: Inositol lipids and signal transduction in the nervous system: an update. J Neurochem 1992; 58:18-38
28. Nahorski SR, Ragan CI, Challiss RAJ: Lithium and the phosphoinositide cycle: an example of uncompetitive inhibition and its pharmacological consequences. Trends Pharmacol Sci 1991; 12:297-303
29. Kofman O, Belmaker RH: Biochemical, behavioral and clinical studies of the role of inositol in lithium treatment and depression. Biol Psychiatry 1993; 34:839-852
30. Kippert F: Lithium affects the ultradian clock of Schizosaccaromyces pombe by inhibition of inositol monophosphatase. Biochem Soc Trans 1997; 25:8602
31. Jope RS, Williams MB: Lithium and brain signal transduction systems. Biochem Pharmacol 1994; 47:429-441
32. Moore GJ, Bebchuk JM, Parrish JK, Faulk MW, Arfken CL, Strahl-Bevacqua J, Manji HK: Temporal dissociation between lithium-induced frontal myo-inositol changes and clinical response in manic-depressive illness. Am J Psychiatry (in press)
33. Stambolic V, Ruel LR, Woodgett JR: Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signaling in intact cells. Curr Biol 1996; 6:1664-1668; correction, 1997; 7:196
34. Lucas FR, Goold RG, Gordon-Weeks PR, Salinas PC: Inhibition of GSK-3beta leading to the loss of phosphorylated MAP-1B is an early event in axonal remodelling induced by WNT-7a or lithium. J Cell Sci 1998; 111:1351-1361
35. Chen G, Huang LD, Jiang YM, Manji HK: The mood stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J Neurochem 1999; 72:1327-1330
36. Lin A, Smeal T, Binetruy B, Deng T, Chambard JC, Karin M: Control of AP-1 activity by signal transduction cascades. Adv Second Messenger Phosphoprotein Res 1993; 28:255-260
37. Manji HK, Lenox RH: Long-term action of lithium: a role for transcriptional and posttranscriptional factors regulated by protein kinase C. Synapse 1994; 16:11-28
38. Nishizuka Y: Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 1992; 258:607-613
39. Stabel S, Parker PJ: Protein kinase C. Pharmacol Ther 1991; 51:71-95
40. Manji HK, Etcheberrigaray R, Chen G, Olds JL: Lithium decreases membrane-associated protein kinase C in hippocampus: selectivity for the alpha isozyme. J Neurochem 1993; 61: 2303-2310
41. Manji HK, Bebchuk JM, Moore GJ, Glitz D, Hasanat K, Chen G: Modulation of CNS signal transduction pathways and gene expression by mood stabilizing agents: therapeutic implications. J Clin Psychiatry 1999; 60(suppl 2):27-39
42. Lenox RH, Watson DG, Patel J, Ellis J: Chronic lithium administration alters a prominent PKC substrate in rat hippocampus. Brain Res 1992; 570:333-340
43. Lenox RH, McNamara RK, Watterson JM, Watson DG: Myristoylated alanine-rich C kinase substrate (MARCKS): a molecular target for the therapeutic action of mood stabilizers in the brain? J Clin Psychiatry 1996; 57(suppl 13):23-31
44. Chen G, Manji HK, Hawver DB, Wright CB, Potter WZ: Chronic sodium valproate selectively decreases protein kinase C α and ε in vitro. J Neurochem 1994; 63:2361-2364
45. Manji HK, Bersudsky Y, Chen G, Belmaker RH, Potter WZ: Modulation of PKC isozymes and substrates by lithium: the role of myo-inositol. Neuropsychopharmacology 1996; 15:370-382
46. Morgan JI, Curran TE: Proto-oncogenes: beyond second messengers, in Psychopharmacology: The Fourth Generation of Progress. Edited by Bloom FE, Kupfer DJ. New York, Raven Press, 1995, pp 631-642
47. Asghari V, Wang JF, Reiach JS, Young LT: Differential effects of mood stabilizers on Fos/Jun proteins and AP-1 DNA binding activity in human neuroblastoma SH-SY5Y cells. Brain Res Mol Brain Res 1998; 58:95-102
48. Ozaki N, Chuang DM: Lithium increases transcription factor binding to AP-1 and cyclic AMP-responsive element in cultured neurons and rat brain. J Neurochem 1997; 69:2336-2344
49. Kumer SC, Vrana KE: Intricate regulation of tyrosine hydroxylase activity and gene expression. J Neurochem 1996; 67:443-461
50. Chen G, Yuan PX, Jiang Y, Huang LD, Manji HK: Lithium increases tyrosine hydroxylase levels both in vivo and in vitro. J Neurochem 1998; 70:1768-1771
51. Drevets WC, Price JL, Simpson JR Jr, Todd RD, Reich T, Vannier M, Raichle ME: Subgenual prefrontal cortex abnormalities in mood disorders. Nature 1997; 38:824-827
52. Ketter TA, George MS, Kimbrell TA, Willis MW, Benson BE, Post RM: Neuroanatomical models and brain-imaging studies, in Bipolar Disorder: Biological Models and Their Clinical Application, Edited by Young LT, Joffe RT. New York, Marcel Dekker, 1997, pp 179-217
53. Rajkowska G, Miguel-Hidalgo JJ, Wei J, Dilley G, Pittman SD, Meltzer HY, Overholser JC, Roth BL, Stockmeier CA: Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression. Biol Psychiatry 1999; 45:1085-1098
54. Liang P, Pardee AB: Differential display of eukaryotic messenger RNA by means of the polymerase chain reaction. Science 1992; 257:967-971
55. Ikonomov OC, Jacob MH: Preferential identification of differentially expressed mRNAs of moderate to low abundance in a microscopic system using selected primers, in Gene Cloning and Analysis by RT-PCR. Edited by Siebert P, Larrick JW. Natick, Mass, BioTechniques Books (Eaton Publishing), 1998, pp 171-181
56. Wang JF, Young LT: Differential display PCR reveals increased expression of 2′,3′-cyclic nucleotide 3′-phosphodiesterase by lithium. FEBS Lett 1996; 386:225-229
57. Manji HK, Zeng WZ, Huang LD, Ikonomov OC, Chen G: A new common transcriptional target for the mood-stabilizing agents lithium and valproic acid. Abstracts of the Society for Neuroscience 1997; 23:796.12
58. Duman RS, Heninger GR, Nestler EJ: A molecular and cellular theory of depression. Arch Gen Psychiatry 1997; 54:597-606
59. Flint J, Corley R: Do animal models have a place in the genetic analysis of quantitative human behavioral traits? J Mol Med 1996; 74:515-521
60. Kirsch J, Meyer G, Betz H: Synaptic targeting of ionotropic neurotransmitter receptors. Mol Cell Neurosci 1996; 8:93-98
61. Ikonomov OC, Zeng WZ, Jiang Y, Chen G, Manji HK: Gephyrin and ETO mRNA levels are differentially affected by chronic lithium treatment. Abstracts of the Society for Neuroscience 1997; 23:796.12
62. Ikonomov OC, Stoynev AG, Shisheva AC: Integrative coordination of circadian mammalian diversity: neuronal networks and peripheral clocks. Prog Neurobiol 1998; 54:87-97
63. Ralph MR, Foster RG, Davis FC, Menaker M: Transplanted suprachiasmatic nucleus determines circadian period. Science 1990; 247:975-978
64. Healy D, Waterhouse JM: The circadian system and the therapeutics of the affective disorders. Pharmacol Ther 1995; 65: 241-263
65. Subramanian P, Menon VP, Arokiam FV, Rajakrishnan V, Balamurugan E: Lithium modulates biochemical circadian rhythms in Wistar rats. Chronobiol Int 1998; 15:29-38
66. Zamoshchina TA, Matveenko AV, Saratikov AS: Effects of lithium hydroxybutyrate on circadian rhythms of rest-activity and sleep structure in experimental animals. Biull Eksp Biol Med 1992; 113:152-154
67. Lakin-Thomas PL: Evidence against a direct role for inositol phosphate metabolism in the circadian oscillator and the blue-light signal transduction pathway in Neurospora crassa. Biochem J 1993; 292:813-818
68. Welsh DK, Logothetis DE, Meister M, Reppert SM: Individual neurons dissociated from rat suprachiasmatic nucleus express independently phased circadian firing rhythms. Neuron 1995; 14:697-706
69. Schibler U: Circadian rhythms: new cogwheels in the clock-works. Nature 1998; 393:620-621
70. Zylka MJ, Shearman LP, Weaver DR, Reppert SM: Three period homologs in mammals: differential light responses in the suprachiasmatic circadian clock and oscillating transcripts outside of brain. Neuron 1998; 20:1103-1110